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MEKANISME MOLEKULAR MITRAGYNINE ATAS PERENCATAN 
SALURAN HERG1A/1B  
 
ABSTRAK 
Daun Mitragyna speciosa Korth (M. speciosa), pada umumnya dikenali 
sebagai daun ketum di Malaysia, telah digunakan secara meluas untuk merawat 
penyakit yang lazim seperti jangkitan usus, sakit otot, batuk, cirit-birit, kencing manis, 
darah tinggi dan untuk memperbaiki peredaran darah. Walau bagaimanapun, keadaan 
keselamatan dan potensi penyalahgunaan tumbuhan ini yang mempamerkan kesan 
ketagihan semakin membimbangkan. Profil keselamatan tumbuhan ini tidak 
dijelaskan sepenuhnya. Ether-a-go-go-related gen manusia 1 (hERG1) mengekod 
subunit yang mendasari pembentukan liang protein saluran lambat kalium (IKr). 
Sekatan farmakologi atas IKr boleh menyebabkan sindrom perolehan QT panjang yang 
bakal mengakibatkan aritmia jantung yang boleh membawa maut. Justeru, kajian ini 
bertujuan untuk menyelidik kesan mitragynine, sebatian bioaktif utama dalam ekstrak 
daun ketum, atas perencatan saluran hERG1a/1b dengan menggunakan kaedah in 
silico dan in vitro. Simulasi dok telah dijalankan dengan menggunakan model 
homologi hERG1 dan interaksi serta affiniti pengikatan antara molekul telah dianalisis. 
Sel rekombinan HEK293-hERG1a/1b telah dihasilkan untuk menilai kesan 
mitragynine atas arus dan ungkapan mRNA hERG1a/1b masing-masing dengan 
menggunakan analisis sistem patch-clamp seluruh sel dan RT-qPCR. Di samping itu, 
ungkapan protein saluran hERG1a/1b telah dikaji dengan menggunakan analisis 
Western blot dan imuno pendarfluor. Simulasi dok mencadangkan mitragynine 
berkemungkinan merupakan perencat hERG1 dengan membentuk interaksi π dengan 
xxiii 
 
asid amino yang penting bagi saluran hERG1, iaitu Tyr652 and Phe656. Sistem patch-
clamp seluruh sel yang menggunakan sel rekombinan HEK293-hERG1a/1b telah 
berjaya dihasilkan dan disahkan dengan beberapa penyekat hERG1 yang diketahui. 
Sertindole, terfenadine, propafenone dan fluoxetine masing-masing mendedahkan 
nilai IC50 17.44 nM (h = 0.76), 66.44 nM (h = 0.84), 361.8 nM (h = 1.56) dan 640.5 
nM (h = 1.19). Mitragynine didapati menyekat arus hERG1a/1b dengan IC50 332.7 
nM (h = 0.61). Namun, mitragynine tidak menunjukkan kesan penyekatan yang nyata 
atas ungkapan mRNA hERG1a/1b (p > 0.05). Di samping itu, ungkapan protein 
hERG1a/1b tidak terjejas pada kepekatan yang rendah (p > 0.05). Sebaliknya, analisis 
Western blot dan imuno pendarfluor menunjukkan pengurangan yang nyata dalam 
ungkapan protein hERG1a pada 10 µM (p = 0.0217 dan 0.0028). Akan tetapi, 
ungkapan protein hERG1b tidak terjejas (p = 0.4677 dan 0.2667). Analisis Western 
blot telah menunjukkan peningkatan yang nyata dalam ungkapan protein hERG1a 
yang tidak berglikolisis penuh (cg-hERG1a) (p = 0.0188), dan pengurangan yang 
nyata dalam ungkapan protein hERG1a yang berglikolisis penuh (fg-hERG1a) (p = 
0.0217). Pemerhatian ini mencadangkan aliran trafik hERG1a telah terjejas. Namun, 
mitragynine tidak menyekat interaksi antara cg-hERG1a dengan chaperone sitoplasma, 
Hsp70 dan Hsp90. Sebaliknya, mitragynine meningkatkan interaksi antara cg-
hERG1a dengan Hsp90 (p = 0.0101). Pemerhatian ini mencadangkan bahawa 
mitragynine menyekat aliran trafik hERG1a dengan menggunakan mekanisme yang 
lain. Kesimpulannya, mitragynine merencat arus hERG1a/1b dengan penyekatan terus 
saluran hERG1a/1b pada kepekatan yang rendah serta pengurangan ungkapan protein 
hERG1a/1b pada kepekatan yang tinggi. Kajian ini mencadangkan alkaloid ini 
berkemungkinan menyebabkan ketoksikan terhadap jantung.         
xxiv 
 
MOLECULAR MECHANISMS OF MITRAGYNINE INHIBITION ON 
HERG1A/1B CHANNEL 
 
ABSTRACT 
The leaves of Mitragyna speciosa Korth (M. speciosa), commonly known as 
ketum in Malaysia, have been widely used to treat common illnesses such as intestinal 
infections, muscle pain, cough, diarrhea, diabetes, hypertension and to improve blood 
circulation. Nevertheless, there are growing concerns about the safety and abuse or 
misuse potentials of the plant which exhibits addictive effects. The safety profile of 
the plant is not fully elucidated. The human ether-a-go-go-related gene 1 (hERG1) 
encodes the pore-forming subunit underlying cardiac rapidly delayed rectifier 
potassium current (IKr). Pharmacological blockade of the IKr can cause acquired long 
QT syndrome, which may lead to lethal cardiac arrhythmias. Hence, this study aims 
to investigate the effects of mitragynine, the major bioactive compound derived from 
the leave extracts of ketum, on hERG1a/1b channel inhibition, using both in silico and 
in vitro approaches. Docking simulations were performed using a hERG1 homology 
model and their molecular interactions and binding affinities were analyzed. A 
recombinant HEK293-hERG1a/1b cell line was established and subsequently used to 
evaluate the effects of mitragynine on hERG1a/1b current and mRNA expression 
using whole cell patch clamp and RT-qPCR analyses respectively. In addition, the 
protein expression of hERG1a/1b channels was studied using both Western blot and 
immunofluorescence analyses. In silico study shows that mitragynine is likely a 
hERG1 inhibitor by forming π interactions with the important residues, Tyr652 and 
Phe656, of the hERG1 channel. Whole cell patch clamp system using the recombinant 
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HEK293-hERG1a/1b cell line was successfully established and verified using several 
known hERG1 blockers. Sertindole, terfenadine, propafenone and fluoxetine revealed 
IC50 values of 17.44 nM (h = 0.76), 66.44 nM (h = 0.84), 361.8 nM (h = 1.56) and 
640.5 nM (h = 1.19) respectively. On the other hand, mitragynine was found to inhibit 
the current with an IC50 of 332.7 nM (h = 0.61). However, mitragynine did not show 
significant inhibitory effect (p > 0.05) on the hERG1a/1b mRNA expression. At lower 
concentration, the hERG1a/1b protein expression was not affected (p > 0.05). 
Interestingly, Western blot and immunofluorescence analyses showed a significant 
reduction in the hERG1a protein expression at 10 µM (p = 0.0217 and 0.0028 
respectively), but not hERG1b (p = 0.4677 and 0.2667 respectively). Western blot 
analysis showed an increase in protein expression of core-glycosylated (cg) hERG1a 
(p = 0.0188) but a reduction in expression of fully-glycosylated (fg) hERG1a (p = 
0.0217), suggesting an impaired hERG1a trafficking. Nevertheless, mitragynine did 
not inhibit the interactions between cg-hERG1a and cytosolic chaperones, Hsp70 and 
Hsp90. On the other hand, mitragynine treated cells have up-regulated the hERG1a-
Hsp90 complexes (p = 0.0101), indicating a different trafficking inhibition pathway 
by mitragynine. In conclusion, mitragynine inhibits hERG1a/1b current by direct 
channel blockade at lower concentration and reduces hERG1a/1b channel protein 
expression at higher concentration, suggesting the possibility of the alkaloid to cause 
cardiac toxicity.     
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CHAPTER 1 
INTRODUCTION 
1.1 Problem statement 
In recent years, there has been an increased demand for herbal medicines all 
over the world, including Malaysia. According to World Health Organization (WHO), 
herbal medicines consist of herbs, herbal materials, herbal preparations and finished 
herbal products, which contain parts of plants, other plant materials, or combinations, 
as active ingredients (WHO, 2017). Herbal medicines are widely used by the public 
for general health care, for the prevention or treatment of minor ailments, as well as 
for chronic illnesses (Aziz and Tey, 2009; Sofowora et al., 2013). 
A survey conducted in 2009 indicated that 88.9% and 87.3% of the Malaysian 
population utilized biologically-based remedy such as supplements, vitamins and 
herbs for health problem and health maintenance respectively (Siti et al., 2009). One 
of the key reasons for the public to rely on herbal medicines is that these products are 
relatively inexpensive. In addition, majority of the public believe that herbal medicines 
do not contain harmful chemicals and are free of side effects comparing to 
commercially available pharmaceutical drugs (Law and Soon, 2013). This is not 
always true, especially when herbs are consumed with prescription drugs, over-the-
counter medications, or other herbs, in which drug-herb interactions are very 
commonly reported (Wachtel-Galor and Benzie, 2011; Singh and Zhao, 2017).  
The widespread use of herbal medicines by the Malaysian population is of 
special concern, particularly when herbal medicines are not strictly controlled by the 
Malaysian Drug Control Authority (DCA). The safety and quality assessment of 
herbal medicines by the DCA is restricted to regulation on the content of specified 
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contaminants and adulterants such as microorganisms and heavy metals (Aziz and Tey, 
2009; Chandra Siri et al., 2013). Lack of knowledge and scientific evidence on the 
safety of herbal medicines may pose additional risk to the public. 
Mitragyna speciosa Korth from the Rubiaceae (coffee) family is a medicinal 
plant which is native to countries in South-East Asia, especially in Thailand, Malaysia, 
Indonesia and Papua New Guinea. It is commonly known as “ketum” or  “Biak-Biak” 
in Malaysia or “kratom” in Thailand (Ahmad and Aziz, 2012; Hassan et al., 2013). In 
Malaysia, the plant is predominantly found in the northern states, especially Perlis and 
Kedah, and it is commonly sold as beverages and teas (Vicknasingam et al., 2010; 
Ahmad and Aziz, 2012). Ketum leaves have been used by natives to treat common 
illnesses, for instance, intestinal infections, cough, diarrhea, muscle pain, diabetes and 
hypertension, as well as to improve blood circulation (Adkins et al., 2011; Ahmad and 
Aziz, 2012; Hassan et al., 2013). Moreover, the leaves are popular for their energizing 
and pain alleviating effects that are known to possess psychostimulant- and addictive-
like properties, depending on the dosage taken (Singh et al., 2014). 
Apart from traditional uses, ketum is often misused for recreational purposes. 
A survey conducted in two northern states of Malaysia (Kedah and Penang) revealed 
that 90% of the subjects relied on ketum as an inexpensive alternative to the more 
expensive opiates, and 84% used it to alleviate their opioid withdrawal symptoms 
(Vicknasingam et al., 2010). Another recent study indicated that more than half of the 
regular ketum users developed severe ketum dependence problems, whereas 45% 
showed a moderate ketum dependence (Singh et al., 2014).  
Usage of ketum is no longer restricted to its native country. In recent years, 
ketum containing preparations, which are in the form of dried leaf, resin or crude 
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extracts, are widely accessible on the internet and users can conveniently buy them 
online (Schmidt et al., 2011; Cinosi et al., 2015). Ketum is generally consumed 
deliberately to gain the desirable effects of euphoria, to manage opiate withdrawal, or 
to ease chronic pain. Most users prefer self-treat to avoid the stigma of being classified 
as drug-dependent (Ramanathan and Mansor, 2014). Several poisoning and fatal cases 
related to ketum and mitragynine (the main alkaloid in the leave extracts of ketum) 
have been reported. However, the underlying causes remain ambiguous (Boyer et al., 
2008; Nelsen et al., 2010; Kronstrand et al., 2011; Neerman et al., 2013).  
Cardiac toxicity is one of the major reasons responsible for the suspension of 
preclinical or clinical drug discovery programs, for severe adverse drug reactions, and 
for withdrawal of licensed drugs (Schramm et al., 2014). Between 1957 and 2007, 
there were 47 cases of post-marketing withdrawal of drugs, in which 45% of these 
were due to concerns about cardiac toxicity (Redfern et al., 2010). Likewise, 27% of 
the potential new drug molecules failed in the pre-clinical stage since 1990s due to 
cardiac toxicity (Turner et al., 2014). The risk of developing Torsade de Pointes (TdP), 
a lethal cardiac arrhythmia which is portrayed by long QT interval in 
electrocardiogram, has been the main reason for the removal of approximately 26% of 
post-marketed drugs between 1990 and 2005 (Valentin, 2010; Kothari et al., 2015).  
The human ether-a-go-go related gene (hERG1) channel is the currently most 
important target for cardiac safety evaluation (Gintant et al., 2016; Grandi et al., 2017). 
Inhibition of hERG1 by a wide range of drug molecules can prolong repolarization of 
the cardiac action potential and eventually lead to serious complication, such as TdP 
and sudden cardiac death (Kallergis et al., 2012). To reduce cardiac risks following 
drug development, both the pharmaceutical industry and U.S. Food and Drug 
Administration (FDA) have mandated in vitro cardiac toxicity screening early in new 
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chemical entity (NCE) development (FDA, 2005a; Liang et al., 2013). Nevertheless, 
little is known about the hERG1 inhibitory potential of herbal medicines (Schramm et 
al., 2014). To date, several natural compounds under the class of flavonoids (e.g., 
acacetin and naringenin) and alkaloids (e.g., changrolin, dauricine, and lobeline) are 
known as hERG1 blockers in vitro (Zitron et al., 2005; Schramm et al., 2014; De Mieri 
et al., 2015). Furthermore, it was revealed that drinking 1 L of pink grapefruit juice, 
which contains large amounts of naringenin, led to significant QT prolongation in 
healthy volunteers (Zitron et al., 2005). However, the cardiac toxicity of ketum or 
mitragynine is poorly understood. Hence, there is a vital need to evaluate 
comprehensively the potential risks of ketum or mitragynine in hERG1 channel 
inhibition. 
 
1.2 Objectives of study 
1.2.1 General objective 
The general objective of the present work is to determine the molecular 
mechanism of mitragynine inhibition on the hERG1a/1b channel. 
 
1.2.2 Specific objectives 
The specific objectives of the present work are: 
1. To predict interaction of hERG1 with mitragynine and its analogues using an 
in silico approach.  
2. To develop a whole-cell patch-clamp assay using a recombinant HEK293 cell 
line expressing human ether-a-go-go related gene 1a/1b (hERG1a/1b) channel. 
3. To determine the effects of mitragynine on hERG1a/1b current.  
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4. To determine the effects of mitragynine on hERG1a/1b mRNA and protein 
expression.  
5. To determine the effects of mitragynine on the interactions between hERG1a 
protein and cytosolic chaperones Hsp70 and Hsp90. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Mitragynine and its analogues 
Mitragynine is a major bioactive compound isolated from the leave extracts of 
Mitragyna speciosa Korth, which is commonly known as “ketum” in Malaysia. The 
plant is a tall leafy plant which can grow to a normal height of 4 – 9 m and 5 m wide 
and it grows mainly in tropical and sub-tropical regions of South-East Asia and Africa. 
(Hassan et al., 2013). The leaves of the plant are either made into drink, chewed when 
freshly picked, or smoked when dried (Ahmad and Aziz, 2012).  
Ketum is well-known for its addictive properties. The usage of ketum in 
Malaya (Peninsula Malaysia in olden days) was first reported by Burkill in 1935 as a 
wound poultice, remedy for fever and an alternative for opium (Burkill, 1935; Ahmad 
and Aziz, 2012). Traditionally, ketum has been used by the natives to disengage 
addicts from heroin addiction, to cure diarrhea, to treat diabetes as well as to improve 
blood circulation (Chan et al., 2005; Singh et al., 2017). In addition, the leaves of the 
plant have long been consumed by male manual laborers to enhance physical 
endurance and as a means to overcome stress (Vicknasingam et al., 2010; Singh et al., 
2016). Opiate addicts rely on ketum to reduce consumption of more expensive opiates, 
to alleviate opium withdrawal symptoms and to treat chronic pain (Boyer et al., 2008; 
Vicknasingam et al., 2010; Cinosi et al., 2015). Nevertheless, long-term consumption 
of ketum can lead to misuse, abuse, dependence and addiction (Boyer et al., 2008; 
Trakulsrichai et al., 2013; Galbis-Reig, 2016). Typical withdrawal symptoms reported 
include aggression, hostility, excessive tearing, inability to work and jerky movements 
of limbs, whereas long-term usage of ketum has been known to cause symptoms such 
as insomnia, anorexia and weight loss (Suwanlert, 1975; Ahmad and Aziz, 2012).  
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Extensive phytochemical studies carried out since the 1960s have revealed the 
natural occurrence of alkaloids, terpenoids and flavonoids in the plant material of the 
genus Mitragyna (Brown et al., 2017). The major phytochemicals isolated and 
characterized from the plant M. speciosa (ketum) are the alkaloid compounds 
(summarized in Table 2.1) (Beckett et al., 1966a; Beckett et al., 1966b; Shellard et al., 
1978a; Shellard et al., 1978b; Houghton and Said, 1986; Houghton et al., 1991; 
Takayama et al., 1998; Takayama et al., 1999; Takayama et al., 2000; Takayama, 
2004; Kitajima et al., 2006; Hassan et al., 2013; Ali et al., 2014; Brown et al., 2017). 
The main pharmacologically active alkaloids derived from the ketum leaves are the 
indole alkaloids, mitragynine and 7-hydroxymitragynine (7-HMG) (Warner et al., 
2016). Mitragynine, accounting for approximately 12-66% of the total alkaloid 
mixture, appears to be the dominant active alkaloid and is exclusive to the plant 
whereas 7-HMG accounts for only up to 2% (Hassan et al., 2013; Warner et al., 2016).  
The alkaloid content varies depending on stage of maturity or ecotype of the 
plant (Shellard et al., 1978b; Takayama et al., 1998; Leon et al., 2009; Brown et al., 
2017). Depending on ecotype, mitragynine makes up approximately 66% of the total 
alkaloid content in plants of Thai origin, whereas it constitutes only 12% in plants of 
Malaysian origin (Ponglux et al., 1994; Takayama et al., 1998; Brown et al., 2017). 
Furthermore, some of the alkaloids were only found in the Malaysian sample, for 
instance, mitragynaline, 3,4,5,6-tetradehydromitragynine, mitralactonal and 
mitrasulgynine (Takayama et al., 1998; Hassan et al., 2013). On the other hand, the 
major alkaloid derived from the leaves of the plant grown in the United States at the 
University of Mississippi is the oxindole-type mitraphylline, instead of mitragynine 
(Leon et al., 2009; Gogineni et al., 2015). In addition, mitragynine and paynantheine 
were found abundantly in the mature leaves of ketum, whereas speciogynine (Thai  
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Table 2.1 Alkaloid profile of Mitragyna speciosa Korth. 
 
Alkaloid Chemical structure Reference(s) 
Indole alkaloids 
Mitragynine 
 
Beckett et al., 1966b; 
Leon et al., 2009; Ali 
et al., 2014; Lesiak et 
al., 2014; Wang et al., 
2014; Avula et al., 
2015; Lesiak and 
Musah, 2016  
Paynantheine 
 
Beckett et al., 1966b; 
Leon et al., 2009; Ali 
et al., 2014; Lesiak et 
al., 2014; Wang et al., 
2014; Avula et al., 
2015; Lesiak and 
Musah, 2016  
Speciogynine 
 
Beckett et al., 1966b; 
Ali et al., 2014; Lesiak 
et al., 2014; Wang et 
al., 2014; Avula et al., 
2015  
Speciociliatine 
 
Beckett et al., 1966b; 
Ali et al., 2014; Lesiak 
et al., 2014; Wang et 
al., 2014; Avula et al., 
2015   
Ajmalicine 
 
Beckett et al., 1966b; 
Leon et al., 2009; 
Lesiak et al., 2014;  
Lesiak and Musah, 
2016  
Corynantheidine 
 
Beckett et al., 1966b; 
Leon et al., 2009 
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Table 2.1 Continued 
 
Alkaloid Chemical structure Reference(s) 
Isocorynantheidine 
 
Shellard et al., 
1978b; Leon et al., 
2009  
3-isopaynantheine 
 
Shellard et al., 
1978b; Ali et al., 
2014; Wang et al., 
2014; Avula et al., 
2015 
Mitraciliatine 
 
Shellard et al., 1978b 
Lesiak et al., 2014; 
3-dehydromitragynine 
 
Houghton and Said, 
1986 
Mitragynaline 
 
Houghton et al., 
1991; Takayama et 
al., 2001 
Mitragynalinic acid 
 
Houghton et al., 
1991 
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Table 2.1 Continued 
 
Alkaloid Chemical structure Reference(s) 
Corynantheidaline 
 
Houghton et al., 
1991; Takayama et 
al., 2001 
Corynantheidinalinic 
acid 
 
Houghton et al., 
1991 
7-hydroxymitragynine 
 
Ponglux et al., 1994; 
Leon et al., 2009; 
Lesiak et al., 2014; 
Avula et al., 2015; 
Lesiak and Musah, 
2016   
Mitralactonal 
 
Takayama et al., 
1998 
Mitrasulgynine 
 
Takayama et al., 
1998 
3,4,5,6-
tetradehydromitragynine 
 
Takayama et al., 
1998 
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Table 2.1 Continued 
 
Alkaloid Chemical structure Reference(s) 
Mitralactonine 
 
Takayama et al., 
1999 
9-
methoxymitralactonine 
 
Takayama et al., 
2000 
7-
hydroxyspeciociliatine 
 
Kitajima et al., 2006 
7β-hydroxy-7H-
mitraciliatine 
 
Ali et al., 2014; 
Avula et al., 2015  
Oxindole alkaloids 
Mitraphylline 
 
Beckett et al., 1966a; 
Leon et al., 2009; 
Lesiak et al., 2014;  
Lesiak and Musah, 
2016  
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Table 2.1 Continued 
 
Alkaloid Chemical structure Reference(s) 
Isomitraphylline 
 
Beckett et al., 1966a; 
Leon et al., 2009 
Speciophylline 
 
Beckett et al., 1966a 
Specionoxeine 
 
Trager et al., 1968; 
Shellard et al., 1978b 
Isospecionoxeine 
 
Trager et al., 1968; 
Shellard et al., 1978b 
Mitrafoline 
 
Hemingway et al., 
1975; Shellard et al., 
1978a 
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Table 2.1 Continued 
 
Alkaloid Chemical structure Reference(s) 
Isomitrafoline 
 
Hemingway et al., 
1975; Shellard et al., 
1978a 
Speciofoline 
 
Hemingway et al., 
1975; Shellard et al., 
1978a 
Isospeciofoline 
 
Hemingway et al., 
1975; Shellard et al., 
1978a; Ali et al., 
2014; Avula et al., 
2015 
Mitragynine oxindole 
A 
 
Shellard et al., 1978a 
Mitragynine oxindole 
B 
 
Shellard et al., 1978a 
Corynoxine A 
 
Shellard et al., 1978a; 
Ali et al., 2014; Wang 
et al., 2014; Avula et 
al., 2015 
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Table 2.1 Continued 
 
Alkaloid Chemical structure Reference(s) 
Corynoxine B 
 
Shellard et al., 1978a; 
Ali et al., 2014; Wang 
et al., 2014; Avula et 
al., 2015 
Rhynchophylline 
 
Shellard et al., 1978a; 
Lesiak et al., 2014;  
Lesiak and Musah, 
2016 
Isorhynchophylline 
 
Shellard et al., 1978a 
Rhyncociline 
 
Shellard et al., 1978a 
Ciliaphylline 
 
Shellard et al., 1978a 
Corynoxeine 
 
Shellard et al., 1978a; 
Kitajima et al., 2006; 
Lesiak et al., 2014; 
Lesiak and Musah, 
2016 
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Table 2.1 Continued 
 
Alkaloid Chemical structure Reference(s) 
Isocorynoxeine 
 
Kitajima et al., 2006 
Isospeciofoleine 
 
Ali et al., 2014; 
Avula et al., 2015 
Isorotundifoline 
 
Ali et al., 2014; 
Avula et al., 2015 
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samples) as well as mitragynaline and corynantheidaline (Malaysian samples) 
appeared to be the dominant alkaloids in the very young leaves of ketum, suggesting 
the variation of alkaloid contents in plants of different maturity (Shellard et al., 1978a; 
Shellard et al., 1978b; Houghton et al., 1991; Brown et al., 2017). 
The usage of ketum has gained increasing popularity in the Western countries 
since the herbal products can be easily accessible over the internet with minimal 
regulation of their sale (Adkins et al., 2011; Singh et al., 2016). People consume them 
primarily for recreational purposes, to ease dependence on alcohol, and to cure anxiety 
and depression (McWhirter and Morris, 2010; Cinosi et al., 2015). Due to the concerns 
over addiction, possessing or selling ketum leaves or preparations in any form are 
prohibited in Malaysia, Thailand, Australia and Myanmar, and are listed as controlled 
drugs in many European Union countries, such as Denmark, Poland and Sweden 
(Hassan et al., 2013). Despite the tree and its leaves being illegal, there is still a 
widespread misuse of ketum by the locals in Malaysia and Thailand (Adkins et al., 
2011; Singh et al., 2016). In August 2016, the US Drug Enforcement Administration 
(DEA) announced its plans to list ketum, mitragynine and 7-HMG as controlled 
substances. However, the plan was temporary put on hold due to public outcry 
(Prozialeck, 2016). Currently, ketum and ketum-derived drugs are legal in the US, 
except in certain states like Alabama, Arkansas, Indiana, Tennessee, Vermont and 
Wisconsin (Prozialeck, 2016). Meanwhile, ketum is legally cultivated in Indonesia 
and exported on large scale to Asia, Europe and North America, making it harder for 
the authorities to control the access of ketum (Hassan et al., 2013). 
In spite of the wide range of pharmacological effects, reports of toxicity related 
to ketum use are scarce. Most of the in vivo studies involved the acute oral toxicity of 
ketum extracts in animal models. In addition, clinical toxicological investigations were 
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limited to a few human case-reports concerning the toxic effect of ketum extracts 
following short or long term consumption (Sabetghadam et al., 2013a). Ketum and its 
related products have been linked to severe drug toxicity. Cases of ketum use 
associated with seizures have been reported after co-administering the herb with 
modafinil (Boyer et al., 2008) and Datura stramonium (Nelsen et al., 2010). Majority, 
but not all, of the cases linked to death involved those who had abused other substances 
along with ketum or had histories of alcohol dependence or heroin abuse (Singh et al., 
2016). Ketum has been shown to cause serious adverse effects, such as elevated blood 
pressure, nephrotoxic effects, impaired cognition and behavior, dependence potential, 
and hepatic failure (Apryani et al., 2010; Harizal et al., 2010; Kapp et al., 2011; Cinosi 
et al., 2015; Yusoff et al., 2016). However, the cardiac toxicity of ketum and its 
analogues is not clearly known (Lu et al., 2014).  
Lu and co-workers (2014) reported an in vitro cardiac toxicity study of 
mitragynine and its analogues using recombinant HEK293 cell expressing human 
ether-a-go-go-related gene 1a channel (HEK293-hERG1a) and human induced 
pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). They found that 10 µM 
mitragynine significantly reduced the rapid outward delayed rectifier potassium 
current (IKr) current in HEK293-hERG1a. In addition, mitragynine, paynantheine, 
speciogynine and speciociliatine dosage-dependently (0.1 – 100 µM) suppressed IKr 
in hiPSC-CMs by 67% - 84% with IC50 values ranging from 0.91 to 2.47 µM. 
Furthermore, mitragynine at 10 µM was found to significantly prolong the action 
potential duration (APD) at 50 and 90% repolarization respectively (APD50 and 
APD90). They concluded that these alkaloids may trigger TdP via inhibition of IKr in 
human cardiomyocytes (Lu et al., 2014). Nevertheless, the effects of mitragynine on 
channel trafficking remained unknown. Apart from acute hERG1 inhibition via 
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channel blockade, hERG1 channel trafficking defect represents the alternative yet 
more chronic cellular mechanism of hERG1 inhibition (Steele et al., 2007; Nogawa 
and Kawai, 2014).  
 
2.2 The cardiac action potential 
A body surface electrocardiogram (ECG) demonstrates the 
electrophysiological events taking place during impulse generation and conduction in 
the heart. Each heartbeat starts as an electrical stimulus generated in the sinoatrial (SA) 
node and is rapidly spreading out through the atria. The impulse from the SA node 
eventually passes through the atrioventricular (AV) node and rapidly propagates to 
both ventricles via the His-Purkinje system. The ‘P’ wave on the ECG measurement 
reflects the combined electrical activity of action potential depolarization in the atria. 
The QRS complex represents the action potential depolarization occurring in the 
ventricles, whereas the T wave corresponds to the ventricular repolarization. Hence, 
the QT interval of an ECG, which is measured in milliseconds (ms), demonstrates the 
duration of the ventricular depolarization and repolarization, plus the time associated 
with transmission across the cardiac muscles (Figure 2.1) (Finlayson et al., 2004; 
Amin et al., 2010; Qu et al., 2014).  
The generation of cardiac action potential is contributed by the selective 
permeability of ion channels distributed on the cardiomyocytes membrane, as shown 
in Figure 2.2. The inward depolarizing currents, primarily through Na+ and Ca2+ 
channels, contribute to normal depolarization, whereas outward repolarizing currents, 
predominantly through K+ channels, result in repolarization (van Noord et al., 2010). 
The human ventricular action potential consists of five sequential phases (phases 0 to 
4). Initially, the cell is polarized near to the equilibrium potential for potassium ions  
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Figure 2.1 The electrical activity of the heart presented on the surface 
electrocardiogram (ECG). The ‘P’ wave reflects the combined electrical activity of 
action potential depolarization in the atria. The QRS complex represents the action 
potential depolarization in the ventricles, whereas the T wave corresponds to the 
ventricular repolarization. (Adapted from Amin et al., 2010 and Qu et al., 2014)  
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Figure 2.2 The ventricular cardiac action potential and cardiac ion channels. The 
upstroke (phase 0) is triggered by the large inward Na+ current (INa). The rest of the 
action potential (phase 1 to 4) is controlled by the interplay of depolarizing Ca2+ 
channels (mainly Cav1.2) and repolarizing K+ channels that regulate the transient 
outward current (It0), the rapid and slow delayed rectifiers currents (IKr and IKs) and 
the inward rectifier current (IK1). (Adapted from Pollard et al., 2010 and George, 2013)  
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(EK) due to the high K
+ conductance at rest (phase 4). A rapid depolarization of the 
membrane (phase 0) is triggered by the large inward Na+ current. Repolarization is 
much slower and occurs in three phases. A brief partial repolarization, which lasts only 
a few milliseconds, follows rapidly (phase 1); this is caused by inactivation of fast Na+ 
channels and a transient outward current (It0), comprising of two components, one a 
Cl- current, and the other by a K+ current. A much slower rate of repolarization, known 
as the plateau phase (phase 2), of the action potential then follows; this is a dynamic 
equilibrium between inward movement of Ca2+ through L-type calcium channels and 
outward movement of K+. The plateau phase delays the cardiac action potential 
duration because the K+ channels that repolarize the membrane either activate slowly, 
inactivate rapidly, or conduct less current at positive transmembrane potentials. A long 
action potential allows sufficient time for influx of extracellular Ca2+ for optimum 
excitation-contraction coupling and also renders the cardiomyocytes comparatively 
refractory to premature excitation. Subsequently, the cell membrane slowly 
repolarizes when K+ efflux exceeds Ca2+ influx. This repolarization (phase 3) 
increases the conductance of some K+ channels while reduces the Ca2+ current, 
resulting in a net outward positive current. The augmenting K+ current rapidly induces 
complete repolarization and returns the membrane potential of the cardiac muscle cells 
to its original resting level (Finlayson et al., 2004; Sanguinetti and Tristani-Firouzi, 
2006; Zünkler, 2006; Pollard et al., 2010; George, 2013).  
There are three major K+ currents involving in the repolarization of ventricular 
myocytes action potential, namely the transient outward K+ current (It0), the delayed 
rectifier K+ current (IK) and the inward rectifier K
+ currents (IK1). It0 contributes to the 
phase 1 repolarization of the action potential, whereas IK1 maintains the resting 
membrane potential and leads to the late repolarization phase (Zünkler, 2006; Hancox 
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et al., 2008; Jeevaratnam et al., 2017). IK is the major outward current that is 
responsible in mediating cardiac action potential repolarization, and thus, is crucial in 
determining the duration of the action potential. Noble and Tsien (1969) first provided 
evidence for two kinetically distinct components of the IK in cardiac myocytes, which 
they named Ix1
 and Ix2 (Noble and Tsien, 1969).  In 1990, Sanguinetti and Jurkiewicz 
demonstrated that the two components differed in pharmacological sensitivity, in 
which certain class III antiarrhythmic drugs selectively blocked the rapid component, 
which they named IKr, whereas the slow component, IKs was highly sensitive to 
activation by β-adrenergic stimulation (Sanguinetti and Jurkiewicz, 1990).  
Subsequently, the presence of both components was proven in human ventricular 
myocytes (Li et al., 1996; Grant, 2009; Jeevaratnam et al., 2017).  
 
2.3 Long QT syndrome (LQTS) 
Long QT syndrome (LQTS) is a disorder portrayed by delayed ventricular 
myocyte repolarization, which is illustrated by abnormal prolongation of the QT 
interval on the body surface ECG (Figure 2.3) (van Noord et al., 2010; Barsheshet et 
al., 2014; Gintant et al., 2016). The QT interval is influenced by heart rate and hence 
the QT interval is normally corrected for heart rate (QTc). Apart from that, the normal 
and lengthened QTc values rely on gender and age. The American Heart Association, 
the American College of Cardiology Foundation and the Heart Rhythm Society 
(AHA/ACCF/HRS) Recommendations for the Standardization and Interpretation of 
the Electrocardiogram recommended that the QTc greater than 450 ms and 460 ms in 
adult males and adult females, respectively, be regarded as a prolonged QT interval, 
whereas QTc shorter than 390 ms be considered a short QT interval  (Rautaharju et 
al., 2009; Postema and Wilde, 2014). Patients with QTc greater than 500 ms are  
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Figure 2.3 Relationship between (A) delayed repolarization, (B) prolonged QT 
interval and (C) Torsade de Pointes (TdP) cardiac-arrhythmia (Adapted from Gintant 
et al., 2016).   
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predisposed to a ventricular tachyarrhythmia, specifically Torsade de Pointes (TdP), 
characterized by continuously twisting of the QRS complexes around the isoelectric 
line of the ECG, which either spontaneously terminates or degenerates into ventricular 
fibrillation, leading to syncope and sudden death (Postema and Wilde, 2014). 
 
2.3.1 Congenital LQTS 
Congenital LQTS is an inherited form of LQTS affecting young otherwise 
healthy individuals and is related to recurrent spontaneous syncope, which often 
results in cardiac arrest and sudden cardiac death due to ventricular tachyarrhythmia 
and fibrillation. The estimated prevalence of LQTS is about 1 in 2,500 live births 
(Finlayson et al., 2004; Crotti et al., 2008; van Noord et al., 2010; Barsheshet et al., 
2014). 
The first incidence of congenital LQTS may have been depicted by Meissner 
in Germany in 1856 (Meissner, 1856). He described a deaf girl who collapsed and died 
while being reprimanded at school. The girl had two brothers who also died suddenly 
after a severe fright or intense fury. This report preceded the development of ECG and 
thus the QT intervals of this family were not interpreted (Meissner, 1856; Vincent, 
2002; Finlayson et al., 2004). It was more than a century later when Jervell and Lange-
Nielsen (1957) presented the electrocardiographic basis for LQTS. In a family with 
six siblings, four were deaf and suffered repeated syncope during exercise or without 
apparent cause. Three of them died suddenly, at the ages of 4, 5 and 9 years 
respectively. Electrocardiographic studies in three of the cases demonstrated a distinct 
QT interval prolongation. No apparent abnormality of the heart was observed (Jervell 
and Lange-Nielsen, 1957; Vincent, 2002; Finlayson et al., 2004). Thereafter, Romano 
and Ward reported families with a cardiac abnormality almost identical to that 
described by Jervell and Lange-Nielsen but with normal hearing, suggesting a similar 
